8-K - Crinetics Pharmaceuticals, Inc. | StockGist

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K, including in Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the

Regulation Fd

8.01

Other Events. On September 25, 2025, the FDA approved PALSONIFY for the first-line treatment of adults with acromegaly who had an inadequate response to surgery

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 25, 2025. 104 Cover Page Interactive Data File (embed

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1